Clinical study to investigate the efficacy of rituximab monotherapy after the rituximab combination chemotherapy for previously untreated follicular lymphoma<THF019>
Phase 2
- Conditions
- follicular lymphoma
- Registration Number
- JPRN-UMIN000008017
- Lead Sponsor
- TOHOKU HEMATOLOGY FORUM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1)active double cancer 2)severe infection or severe complication 3)having prior drug allergy 4)prior treated heart failure or renal failure 5)Cirrhosis of the liver 6)HBs-Ag positive 7)Disorder of electrocardiogram, Disorder of heart fanction, severe heart disease 8)pregnant/lactating woman 9)psychosis 10)given systemic steroid 11)Physician's decision of inappropriateness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival at 2 years[2y PFS]
- Secondary Outcome Measures
Name Time Method Best Response Rate, Complete Response Rate, Overall Response Rate, Overall survival, Progression Free Survival, Bcl-2 negative conversion rate, Minimal Residual Disease, Safety